Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.34 |
| ▸ | HTR3B | O95264 | 2/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7631284 | 0.90 | MTNR1A (0.40) | CNR1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17473831 | 0.89 | MMP9 (0.35) | TAS1R3TAS1R1QPCTQPCTLMTNR1A | |
| SCHEMBL13734799 | 0.87 | MAPT (0.33) | QPCTQPCTLMTNR1AALDH1A1L3MBTL1 | |
| SCHEMBL17473828 | 0.87 | ST14 (0.36) | QPCTQPCTLALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13934754 | 0.87 | EPHX1 (0.53) | EPHX1ALDH1A1EPHX2 | |
| SCHEMBL5508626 | 0.86 | NOTUM (0.38) | QPCTQPCTLMTNR1AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31530513 | 0.86 | LMNA (0.37) | QPCTQPCTLALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL17473827 | 0.86 | CYP3A4 (0.41) | L3MBTL1TSHRMEN1KMT2A | |
| Iodide SCHEMBL31530538 | 0.86 | ST14 (0.35) | QPCTQPCTLALDH1A1L3MBTL1SMN1; SMN2 | |
| Iodide SCHEMBL31530522 | 0.86 | ST14 (0.35) | QPCTQPCTLALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116898-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | LTD "VALENTA-INTELLEKT" (RU) | 2024-04-11 | — | — | US | disclosed |
| EP-4335509-A2 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | LTD "VALENTA-INTELLEKT" (RU) | 2024-03-13 | — | — | EP | disclosed |
| US-11845740-B2 | Glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | LTD “Valenta-Intellekt” (RU) | 2023-12-19 | — | — | US | disclosed |
| EP-3632433-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" (RU) | 2020-04-08 | — | — | EP | disclosed |
| US-20200087285-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116898-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | GLS, GLS2, QPCT | CNR1 491/4885EPHX1 1505/4885HTR3E 3920/4885 |
| US-20200087285-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | GLS, GLS2, QPCT | CNR1 598/4885EPHX1 1465/4885HTR3E 3915/4885 |
| US-11845740-B2 | Glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | GLS, GLS2, QPCT | CNR1 659/4885EPHX1 1761/4885HTR3E 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.